Showing results (1071-1080 of 4,634) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|July 16, 2024
Differential functionality of fluoropyrimidine nucleosides for safe cancer therapyTim Holzinger, Julia Frei, Natalia Teresa Jarzebska, et al.
Anti-Cancer Drugs|July 16, 2024
Interference with PLA2G16 promotes cell cycle arrest and apoptosis and inhibits the reprogramming of glucose metabolism in multiple myeloma cells by modulating the Hippo/YAP signaling pathwayHongyan Li, Yi Zhang, Xiaoyu Mou, et al.
Anti-Cancer Drugs|July 15, 2024
Complete and durable regression of leptomeningeal involvement during lorlatinib treatment in a patient with lung cancerGiorgia Guaitoli, Enrica Martinelli, Lucia Trudu, et al.
Anti-Cancer Drugs|July 15, 2024
Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case reportAlicia Martín Roldán, Carolina Alarcón-Payer, María Del Mar Sánchez Suárez, et al.
Anti-Cancer Drugs|July 1, 2024
Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature reviewMingtao Shi, Yongchun Zhang
Anti-Cancer Drugs|June 26, 2024
First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinomaTao Luan, Xinqing Lin, Xiaohong Xie, et al.
Anti-Cancer Drugs|May 14, 2024
Combating anoikis resistance: bioactive compounds transforming prostate cancer therapyShweta Gulia, Prakash Chandra, Asmita Das
Anti-Cancer Drugs|May 8, 2024
Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029)Dan Yang, Xiaomin Li, Xiaoying Xue, et al.
Anti-Cancer Drugs|May 29, 2024
Enhancing the management of locally advanced head and neck malignancies and cases with local/neck recurrence and metastasis through the integration of anlotinib with concurrent radiochemotherapyXiaojing Tie, Hang Li, Ling Gao, et al.
Anti-Cancer Drugs|January 21, 2026
Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancerQiong Sun, Sicheng Du, Jing Meng, et al.
Pageof 464